A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Clinical trial NCT07011732 · RECRUITING

Trial details

NCT number: NCT07011732
Sponsor: Bristol-Myers Squibb
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2025-07-10
Primary completion: 2028-11-24
Enrollment: 426

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.